OQS Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Annuity RevenueThe growing installed base supports recurring consumables and service revenue after initial equipment placement. This annuity-like model can improve revenue visibility, deepen customer relationships, and allow future unit growth and utilisation gains to compound across healthcare markets.
Conservative Balance SheetA debt-free balance sheet with substantial cash gives Nanosonics flexibility to fund product launches, commercial expansion and operational investment without relying heavily on external financing. It also provides resilience if healthcare purchasing cycles or launch spending temporarily pressure cash generation.
CORIS Expansion PotentialRegulatory progress across several major markets materially broadens the addressable opportunity beyond the established trophon franchise. CORIS can create a second growth platform, diversify the product portfolio, and support longer-term expansion if commercial adoption follows the clearances.
Bears Say
APAC Revenue WeaknessThe decline in both APAC annuity and capital revenue indicates weaker regional momentum rather than a single product-line issue. Continued reliance on rental and MES models in markets such as Japan could slow installed-base growth and limit recurring revenue expansion in the region.
Margin And OpEx PressureTariffs, freight costs and elevated launch spending are expected to restrain near-term operating leverage even as revenue grows. If CORIS commercial investment takes longer to convert into meaningful sales, margin recovery and earnings growth could remain pressured over the next several quarters.
Weaker Cash ConversionLower operating cash flow and a sharp free-cash-flow decline suggest that accounting earnings converted less effectively into cash in FY2026. Persistent deterioration would reduce internally funded investment capacity and make the economics of expansion and shareholder returns less flexible.
Nanosonics Limited News
OQS FAQ
What was Nanosonics Limited’s price range in the past 12 months?
Currently, no data Available
What is Nanosonics Limited’s market cap?
Nanosonics Limited’s market cap is CHF519.07M.
When is Nanosonics Limited’s upcoming earnings report date?
Nanosonics Limited’s upcoming earnings report date is Feb 23, 2027 which is in 123 days.
How were Nanosonics Limited’s earnings last quarter?
Nanosonics Limited released its earnings results on Aug 24, 2026. The company reported CHF0.017 earnings per share for the quarter, beating the consensus estimate of CHF0.014 by CHF0.002.
Is Nanosonics Limited overvalued?
According to Wall Street analysts Nanosonics Limited’s price is currently Undervalued.
Does Nanosonics Limited pay dividends?
Nanosonics Limited does not currently pay dividends.
What is Nanosonics Limited’s EPS estimate?
Nanosonics Limited’s EPS estimate is 0.01.
How many shares outstanding does Nanosonics Limited have?
Nanosonics Limited has 299,167,630 shares outstanding.
What happened to Nanosonics Limited’s price movement after its last earnings report?
Nanosonics Limited reported an EPS of CHF0.017 in its last earnings report, beating expectations of CHF0.014. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Nanosonics Limited?
Currently, no hedge funds are holding shares in CH:OQS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanosonics Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF2.15 (― Upside)
CHF2.15 (― Upside)
Blogger Sentiment
Bullish
CH:OQS Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth CHF77.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.25%
12-Months-Change
Fundamentals
Return on Equity
8.16%
Trailing 12-Months
Asset Growth
18.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nanosonics Limited
Nanosonics Limited, along with its subsidiaries, functions as a global infection prevention enterprise with operations in Australia and beyond. The company focuses on the production and distribution of its trophon ultrasound probe disinfection system, including all related supplies and accessories. Additionally, it dedicates resources to the exploration, development, and market launch of innovative infection control, decontamination products, and their associated technologies. Key offerings from Nanosonics include trophon2, an advanced device for high-level disinfection of ultrasound probes; trophon EPR, a low-temperature, high-level disinfection method specifically for intra-cavity ultrasound probes; and Nanosonics AuditPro, a comprehensive solution for managing compliance with infection control workflows. Established in 2000, Nanosonics Limited is headquartered in Macquarie Park, Australia.
OQS Company Deck
OQS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and financial picture: constant-currency revenue and EBIT growth, strong trophon profitability and cash generation, record placements and upgrades, product innovation (trophon3/trophon2 Plus), solid annuity and service growth, a debt-free balance sheet with substantial cash and an active buyback. Management also delivered substantial regulatory and commercial progress for CORIS and set explicit FY'27 guidance that anticipates continued growth. Negative items are present but largely manageable and/or transitional: a Q3 consumables dip due to weather, margin moderation from product mix and currency, APAC softness tied to rental models, and elevated near-term OpEx to fund CORIS commercialization which will weigh on near-term profitability. Overall, highlights substantially outweigh the lowlights, with CORIS viewed as a meaningful long-term growth opportunity while trophon continues as a strong cash engine.View all CH:OQS earnings summariesOQS Stock 12 Month Forecast
Average Price Target
―Ansell
―
Polynovo
―
Paragon Care Limited
―
Trajan Group Holdings Ltd
―
CleanSpace Holdings Ltd.
―